Preoperative neutrophil–lymphocyte and platelet–lymphocyte ratios as independent predictors of T stages in hilar cholangiocarcinoma

References

• Weiss MJ, Cosgrove D, Herman JM, Rastegar N, Kamel I, Pawlik TM. Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbeck’s Archiv Surg. 2014;399(6):679–692. doi:10.1007/s00423-014-1219-1
   PubMed Web of Science ®Google Scholar
• Razumilava N, Gores GJ. Cholangiocarcinoma. The Lancet. 2014;383(9935):2168–2179. doi:10.1016/S0140-6736(13)61903-0
   PubMed Web of Science ®Google Scholar
• Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463–73; discussion 73–5.
   PubMed Web of Science ®Google Scholar
• Nishio H, Nagino M, Nimura Y. Surgical management of hilar cholangiocarcinoma: the Nagoya experience. HPB. 2005;7(4):259–262. doi:10.1080/1365182050037301018333203
   PubMedGoogle Scholar
• Lee SG, Lee YJ, Park KM, Hwang S, Min PC. One hundred and eleven liver resections for hilar bile duct cancer. J Hepatobiliary Pancreat Surg. 2000;7(2):135–141. doi:10.1007/s005340000070135.53410982605
   PubMedGoogle Scholar
• Gazzaniga GM, Filauro M, Bagarolo C, Mori L. Surgery for hilar cholangiocarcinoma: an Italian experience. J Hepatobiliary Pancreat Surg. 2000;7(2):122–127. doi:10.1007/s005340000070122.53410982603
   PubMedGoogle Scholar
• Yi B, Xu AM, Lai EC, et al. Preoperative portal vein embolization for hilar cholangiocarcinoma–a comparative study. Hepato-gastroenterology. 2010;57(104):1341–1346.21443082
   PubMedGoogle Scholar
• Tsao JI, Nimura Y, Kamiya J, et al. Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg. 2000;232(2):166–174.10903592
   PubMed Web of Science ®Google Scholar
• Nguyen KT, Steel J, Vanounou T, et al. Initial presentation and management of hilar and peripheral cholangiocarcinoma: is a node-positive status or potential margin-positive result a contraindication to resection? Ann Surg Oncol. 2009;16(12):3308–3315. doi:10.1245/s10434-009-0701-419774418
   PubMed Web of Science ®Google Scholar
• Hu HJ, Mao H, Shrestha A, et al. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: a single-institution experience in China. World J Gastroenterol. 2016;22(8):2601–2610. doi:10.3748/wjg.v22.i8.260126937148
   PubMed Web of Science ®Google Scholar
• Sugiura T, Nishio H, Nagino M, et al. Value of multidetector-row computed tomography in diagnosis of portal vein invasion by perihilar cholangiocarcinoma. World J Surg. 2008;32(7):1478–1484. doi:10.1007/s00268-008-9547-318347849
   PubMed Web of Science ®Google Scholar
• Yeh TS, Jan YY, Tseng JH, et al. Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings. Am J Gastroenterol. 2000;95(2):432–440. doi:10.1111/j.1572-0241.2000.01763.x10685746
   PubMed Web of Science ®Google Scholar
• Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):155–164. doi:10.1055/s-2004-82889215192788
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Kwon HC, Kim SH, Oh SY, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012;17(3):216–222. doi:10.3109/1354750X.2012.65670522424597
   PubMed Web of Science ®Google Scholar
• Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200(2):197–203. doi:10.1016/j.amjsurg.2009.08.04120122680
   PubMed Web of Science ®Google Scholar
• Xiang S, Lau WY, Chen XP. Hilar cholangiocarcinoma: controversies on the extent of surgical resection aiming at cure. Int J Colorectal Dis. 2015;30(2):159–171. doi:10.1007/s00384-014-2063-z25376337
   PubMed Web of Science ®Google Scholar
• Dreyer SB, Powell AG, McSorley ST, et al. The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer. Ann Surg Oncol. 2017;24(5):1295–1303. doi:10.1245/s10434-016-5684-327873100
   PubMed Web of Science ®Google Scholar
• Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma. World J Surg. 2015;39(6):1501–1509. doi:10.1007/s00268-015-2982-z25670038
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? The Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0
   PubMed Web of Science ®Google Scholar
• Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000;60(1):184–190.10646872
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature0132212490959
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Onoda H, Imai N, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22(3):803–810. doi:10.1245/s10434-014-4048-025190127
   PubMed Web of Science ®Google Scholar
• Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 2011;13(7):499–503. doi:10.1007/s12094-011-0687-921775277
   PubMed Web of Science ®Google Scholar
• Krenn-Pilko S, Langsenlehner U, Thurner EM, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 2014;110(10):2524–2530. doi:10.1038/bjc.2014.16324675383
   PubMed Web of Science ®Google Scholar
• Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol. 2013;35(3):254–261. doi:10.1111/ijlh.1208423590652
   PubMed Web of Science ®Google Scholar
• Egan K, Crowley D, Smyth P, et al. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One. 2011;6(10):e26125. doi:10.1371/journal.pone.002612522022533
   PubMed Web of Science ®Google Scholar
• Hu HJ, Jin YW, Zhou RX, et al. Clinical value of inflammation-based prognostic scores to predict the resectability of hyperbilirubinemia patients with potentially resectable hilar cholangiocarcinoma. J Gastrointest Surg. 2019;23(3):510–517. doi:10.1007/s11605-018-3892-930076591
   PubMed Web of Science ®Google Scholar
• Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104(8):1288–1295. doi:10.1038/bjc.2011.10021448173
   PubMed Web of Science ®Google Scholar
• He C, Mao Y, Lao X, Li S, Lin X. Neutrophil-to-lymphocyte ratio predicts overall survival of patients with combined hepatocellular cholangiocarcinoma. Oncol Lett. 2018;15(4):4262–4268. doi:10.3892/ol.2018.788229541193
   PubMed Web of Science ®Google Scholar
• Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 2013;16(1):55–59. doi:10.4048/jbc.2013.16.1.5523593082
   PubMed Web of Science ®Google Scholar
• Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109(2):416–421. doi:10.1038/bjc.2013.33223799847
   PubMed Web of Science ®Google Scholar
• Mano Y, Shirabe K, Yamashita Y, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg. 2013;258(2):301–305. doi:10.1097/SLA.0b013e318297ad6b23774313
   PubMed Web of Science ®Google Scholar
• Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2008;97(6):513–518. doi:10.1002/jso.2100118335453
   PubMed Web of Science ®Google Scholar
• Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34(1):55–60. doi:10.1016/j.ejso.2007.02.01417448623
   PubMed Web of Science ®Google Scholar
• de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140–3145. doi:10.1200/JCO.2011.35.651921730269
   PubMed Web of Science ®Google Scholar
• Spolverato G, Ejaz A, Kim Y, et al. Tumor size predicts vascular invasion and histologic grade among patients undergoing resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2014;18(7):1284–1291. doi:10.1007/s11605-014-2533-124841438
   PubMed Web of Science ®Google Scholar
• Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009;250(1):141–151. doi:10.1097/SLA.0b013e3181a77e5919561458
   PubMed Web of Science ®Google Scholar